- PR Newswire•21 days agoStockNewsNow.com Publishes New SNNLive Video Interview with ARCA biopharma, Inc. Provides Company Overview and Discusses Clinical Development
LOS ANGELES, Nov. 15, 2016 /PRNewswire/ -- StockNewsNow.com , The Official MicroCap News Source™, today published SNNLive Video Interview with Thomas Keuer, Chief Operating Officer of ARCA biopharma, ...
- Business Wire•21 days ago
ARCA biopharma, Inc. , a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended September 30, 2016, and provided a business update.
- Business Wire•2 months agoARCA biopharma Announces Randomization of First European Patients in GENETIC-AF Phase 2B/3 Clinical Trial
ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to the development of genetically-targeted therapies for cardiovascular diseases, today announced the randomization of the first European patients in the GENETIC-AF Phase 2B/3 clinical trial.
ABIO : Summary for ARCA biopharma, Inc. - Yahoo Finance
ARCA biopharma, Inc. (ABIO)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Day's Range||2.30 - 2.42|
|52 Week Range||2.15 - 5.70|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.36|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|